Glaxo’s Earnings Beat Estimates as New Product Sales Double

  • Profit was 24.5 pence a share; analysts expected 21 pence
  • Weaker British pound helps Glaxo earn more from U.S. sales

GlaxoSmithKline CEO on Performance, Products, Growth

GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, reported second-quarter earnings that beat analysts’ estimates and raised its forecast for the year as sales of new products doubled.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.